Key result
In pregnant women with overweight and obesity, plasma ANGPTL4 concentration at 15 weeks of pregnancy was a significant predictor of excessive gestational weight gain (AUC 0.80).
Why the study?
Is circulating ANGPTL4 associated with gestational weight gain in pregnant women with overweight and obesity?
Observational (n=31)
Yes
Is circulating ANGPTL4 associated with gestational weight gain in pregnant women with overweight and obesity?
Effect estimate: AUC 0.80 (95% CI 0.61-0.99)
p-value: p=<0.01
In pregnant women with overweight and obesity, increasing plasma ANGPTL4 concentrations throughout pregnancy are positively associated with gestational weight gain and could serve as an early marker for excess weight gain.
May flag early excessive gestational weight gain risk; hypothesis-generating and requires prospective validation before clinical adoption.
Angiopoietin-like protein 4 (ANGPTL4) is a circulating protein involved in the regulation of adipose tissue metabolism. However, its role in obesity and pregnancy is unknown. To evaluate the relationship between gestational weight gain (GWG) and circulating concentrations of ANGPTL4 in pregnant women with overweight and obesity, weight gain and fasting maternal blood samples of thirty-one pregnant women was drawn at 15, 24 and 32 weeks of gestation. ANGPTL4 concentrations continuously rose throughout gestation, whereas VEGF and leptin did not show the same trend. NEFA and glycerol concentrations remained stable during pregnancy. In contrast, total concentrations of saturated, monounsaturated and n-6 fatty acids, but not n-3 fatty acids, increased with pregnancy. In multiple regression analysis, the increase in plasma ANGPTL4 and decrease in linoleic acid concentrations were the most significant predictors of GWG, although only ANGPTL4 was significantly associated with the weight gain from early pregnancy (area under the ROC curve was 0.80 p < 0.01(95% CI 0.61-0.99)). In conclusion, in pregnant women with overweight and obesity, an increase in plasma ANGPTL4 concentrations throughout pregnancy is positively associated with GWG and could be used as an early marker of increased susceptibility to excess gestational weight gain.
No takes yet. Share an insight, caveat, or question.
Ortega et al. (2018) conducted an observational in Overweight and obesity in pregnancy (n=31). Plasma ANGPTL4 concentration was evaluated on Prediction of excessive gestational weight gain (higher than recommended) using ANGPTL4 concentration at week 15 (AUC 0.80, 95% CI 0.61-0.99, p=<0.01). In pregnant women with overweight and obesity, plasma ANGPTL4 concentration at 15 weeks of pregnancy was a significant predictor of excessive gestational weight gain (AUC 0.80).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: